Polycythemia vera (PV) is a hematopoietic stem cell (HSC) neoplasm driven by somatic JAK2 mutations, characterized by the overproduction of red blood cells (RBCs) uncoupled from mechanisms that regulate erythropoiesis [1]. This evidence concerns the gene JAK2 and acquired polycythemia vera.